Sionna Therapeutics’ shares fell more than 90% after reporting that its lead asset failed an early study and it is no longer advancing the experimental treatment going forward. Vertex's shares hit an all-time high at one point.
Sionna Therapeutics’ bid to become the next cystic fibrosis drug developer after Vertex Pharmaceuticals has taken a major hit, after Sionna
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts…
The biotech said it will not advance SION-719 as an add-on therapy after the drug missed its key endpoint in a Phase 2a study
A pill from Sionna Therapeutics provided no added benefit when combined with Vertex's cystic fibrosis blockbuster Trikafta, a…
Sionna Therapeutics topline clinical data for cystic fibrosis programs disappoints, opting to discontinue its SION-719 candidate.
Vertex stock surged Monday after its competitor, Sionna, missed the mark for its highly anticipated cystic fibrosis treatment.
Sionna Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Sionna Therapeutics…
Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial
